trending Market Intelligence /marketintelligence/en/news-insights/trending/S8YdNjm-vJF3GgSwy7hokg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Swedish biopharma Hansa Medical to change name

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Swedish biopharma Hansa Medical to change name

Hansa Medical AB (publ) will change its name to Hansa Biopharma AB.

Bolagsverket, also known as the Swedish Companies Registration Office, approved the name change.

The name change was approved by shareholders during the biopharmaceutical company's Dec. 4 extraordinary general meeting.

Lund, Sweden-based Hansa, which focuses on treatment and prevention of rare and severe autoimmune conditions and transplant rejection, said the name change will be implemented in the next days and weeks, and the company's ticker has changed to HNSA from HMED.